BRPI0414968A - preparação de infusão contendo ácido (2r)-2-propiloctanóico como o ingrediente ativo - Google Patents

preparação de infusão contendo ácido (2r)-2-propiloctanóico como o ingrediente ativo

Info

Publication number
BRPI0414968A
BRPI0414968A BRPI0414968-8A BRPI0414968A BRPI0414968A BR PI0414968 A BRPI0414968 A BR PI0414968A BR PI0414968 A BRPI0414968 A BR PI0414968A BR PI0414968 A BRPI0414968 A BR PI0414968A
Authority
BR
Brazil
Prior art keywords
infusion
acid
active ingredient
salt
infusion preparation
Prior art date
Application number
BRPI0414968-8A
Other languages
English (en)
Inventor
Masao Sudoh
Seiichi Tanikawa
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of BRPI0414968A publication Critical patent/BRPI0414968A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"PREPARAçãO DE INFUSãO CONTENDO áCIDO (2R)-2-PROPILOCTANóICO COMO O INGREDIENTE ATIVO". Uma preparação de infusão que contém ácido (2R)-2propiloctanóico ou um sal do mesmo, útil no tratamento de doenças neurodegenerativas, e um íon de metal básico fornecido a partir de um sal de metal de um ácido fraco ou um hidróxido de metal preferivelmente em uma quantidade de cerca de 1 a 5 equivalentes por por equivalente do ácido (2R)-2-própiloctanóico ou um sal do mesmo, opcionalmente em conjunto com outro (s) componente(s) de infusão. Essa preparação de infusão apresenta um valor de pH adequado para administração intravenosa, e é útil em administração intravenosa contínua sem a necessidade de qualquer pré-tratamento tal como dissolução ou diluição antes do uso.
BRPI0414968-8A 2003-10-03 2004-10-01 preparação de infusão contendo ácido (2r)-2-propiloctanóico como o ingrediente ativo BRPI0414968A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003345125 2003-10-03
PCT/JP2004/014896 WO2005032538A1 (ja) 2003-10-03 2004-10-01 (２ｒ)−２−プロピルオクタン酸を有効成分とする輸液製剤

Publications (1)

Publication Number Publication Date
BRPI0414968A true BRPI0414968A (pt) 2006-11-07

Family

ID=34419442

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414968-8A BRPI0414968A (pt) 2003-10-03 2004-10-01 preparação de infusão contendo ácido (2r)-2-propiloctanóico como o ingrediente ativo

Country Status (17)

Country Link
US (1) US20070066686A1 (pt)
EP (1) EP1669066A4 (pt)
JP (1) JP4715516B2 (pt)
CN (1) CN1889941A (pt)
AU (1) AU2004277828A1 (pt)
BR (1) BRPI0414968A (pt)
CA (1) CA2540671A1 (pt)
EC (1) ECSP066476A (pt)
IL (1) IL174691A0 (pt)
IS (1) IS8428A (pt)
MA (1) MA28143A1 (pt)
MX (1) MXPA06003605A (pt)
NO (1) NO20061458L (pt)
RU (1) RU2006114834A (pt)
SG (1) SG146690A1 (pt)
WO (1) WO2005032538A1 (pt)
ZA (1) ZA200602689B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7980168B2 (en) * 2007-06-26 2011-07-19 Maurer Scott D Hot beverage maker with filter deforming member
US20100130619A1 (en) * 2008-11-24 2010-05-27 Joseph Schwarz Pharmaceutical composition for parenteral administration of idebenone
RU2549448C1 (ru) * 2014-05-20 2015-04-27 Екофарм Патент Менеджмент Аг Сбалансированный инфузионный раствор
CN104931424A (zh) * 2015-05-06 2015-09-23 山东师范大学 一种改进的z扫描非线性测量的实验装置及方法
CN109593676B (zh) * 2018-12-21 2023-04-07 江苏大学 一种用于酸菜发酵液中微生物分离的培养基及其制备方法
CN113453548A (zh) * 2019-02-14 2021-09-28 北哥罗夫投资公司 用于保持活的和静态的生物材料的生存力的组合物、其制造方法及用途
RU2699222C1 (ru) * 2019-04-29 2019-09-04 Алексей Владимирович Воронов Солевой электролитный раствор для проведения энтеральных инфузий

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0632008T3 (da) * 1993-06-01 1998-09-23 Ono Pharmaceutical Co Pentansyrederivater
JPH0782146A (ja) * 1993-07-23 1995-03-28 Sagami Chem Res Center 抗痴呆薬
JPH07285911A (ja) * 1994-04-20 1995-10-31 New Japan Chem Co Ltd 脂肪族モノカルボン酸組成物
JPH0853351A (ja) * 1994-08-11 1996-02-27 Sagami Chem Res Center 酵素阻害剤、血管新生抑制剤、および癌転移抑制剤
US6043223A (en) * 1997-11-12 2000-03-28 The Regents Of The University Of California Enhanced opening of abnormal brain tissue capillaries
TWI268921B (en) * 1999-02-18 2006-12-21 Ono Pharmaceutical Co A process for preparing (2R)-2-propyloctanoic acid
WO2001092289A1 (fr) * 2000-05-31 2001-12-06 Japan Science And Technology Corporation Promoteurs de regeneration de tissu cutane contenant le ginsenoside rb1
JP4706950B2 (ja) * 2000-07-18 2011-06-22 小野薬品工業株式会社 アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤
KR100759771B1 (ko) * 2000-07-18 2007-10-04 오노 야꾸힝 고교 가부시키가이샤 성상세포 기능 개선제를 유효 성분으로 함유하는 파킨슨병치료제
CA2453478A1 (en) * 2001-07-18 2003-01-30 Ono Pharmaceutical Co., Ltd. Agent for treatment of cerebral ischemic diseases

Also Published As

Publication number Publication date
IL174691A0 (en) 2006-08-20
NO20061458L (no) 2006-07-03
ZA200602689B (en) 2007-06-27
JP4715516B2 (ja) 2011-07-06
CN1889941A (zh) 2007-01-03
EP1669066A4 (en) 2009-04-29
WO2005032538A1 (ja) 2005-04-14
AU2004277828A1 (en) 2005-04-14
JPWO2005032538A1 (ja) 2006-12-14
EP1669066A1 (en) 2006-06-14
IS8428A (is) 2006-04-25
MXPA06003605A (es) 2006-06-14
RU2006114834A (ru) 2007-11-20
US20070066686A1 (en) 2007-03-22
MA28143A1 (fr) 2006-09-01
ECSP066476A (es) 2007-03-29
CA2540671A1 (en) 2005-04-14
SG146690A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
ECSP066477A (es) Composición farmacéutica que comprende ácido (2r)-2-propiloctanoico como un ingrediente activo
EP1626055A3 (en) Non-mammalian GnRH analogs and uses thereof in the regulation of the immune system
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
TW200500067A (en) Salts of codrugs and uses related thereto
NO20076219L (no) Farmasoytisk formulering med apomorfin for bukkal administrering
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
BRPI0916282B8 (pt) uso de um agonista do receptor-pgi2 no tratamento de insuficiência renal crônica
BR0308316A (pt) Sais de nateglinida
ECSP066476A (es) Preparación de una infusión que comprende ácido (2r)-2-propiloctanoico como ingrediente activo
ATE413177T1 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
ATE539761T1 (de) Mittel für injektionszwecke mit einem antibiotikum und das mittel enthaltende lösung zur injektion
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
MXPA04007183A (es) Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2.
ATE446309T1 (de) Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung
WO2012044783A3 (en) Method of achieving a thymosin beta 4 concentration in a human patient
Dehpour et al. Inhibition of the morphine withdrawal syndrome and the development of physical dependence by lithium in mice
BR112014027213A8 (pt) nova composição de alfentanil para o tratamento de dor aguda
BR112015022084A2 (pt) composições para uso em tratamento de distúrbios oculares com o uso de dipiridamol
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
EP2272537A3 (en) Salts of conjugated psychotropic drugs and processes of preparing same
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
BRPI0410851A (pt) solução aquosa de olanexidina, método de preparação da solução aquosa e desinfetante
BR112015011748A2 (pt) terapia de combinação com volasertib
RU2012114097A (ru) Терапевтический агент против хронической боли
BR0317292A (pt) Derivados de amida de ácido antranìlico e seu uso farmacêutico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.